Seratrodast(AA 2414) is a potent and selective thromboxane A2 receptor (TP) antagonist.

SERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator that activates the Ca2+-dependent ATPase activity of cardiac SR vesicles but not that of skeletal muscle SR vesicles that lack of phospholamban (PLN).

Serdexmethylphenidate is the dextrorotary form of methylphenidate and a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant..

Sermorelin is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH).

Setafrastat is a small molecule hair growth stimulator.

Setiptiline is a serotonin receptor antagonist.

Setiptiline(Org-8282) is a serotonin receptor antagonist.

Setrobuvir (ANA-598) is an experimental drug candidate For the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir. It is currently in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.For the detailed information of Setrobuvir, the solubility of Setrobuvir in water, the solubility of Setrobuvir in DMSO, the solubility of Setrobuvir in PBS buffer, the animal experiment (test) of Setrobuvir, the cell expriment (test) of Setrobuvir, the in vivo, in vitro and clinical trial test of Setrobuvir, the EC50, IC50,and Affinity of Setrobuvir, Please contact DC Chemicals..

Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

SF 2312 is a highly potent, low-nanomolar inhibitor of Enolase with IC50 of 37.9 nM and 42.5 nM for recombinant hENO1 and hENO2 respectively.

SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8.

SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.

SFV785 (SRPIN-785) is a derivative of SRPIN340 that selectively inhibits NTRK1 and MAPKAPK5 kinase, shows anti-viral activity on HCV, DENV and yellow fever viruses.

SG3199 is a PBD dimer warhead component of antibody-drug conjugate (ADC) payload tesirine, demonstrates potently cytotoxic against a panel of human solid tumour and haematological cancer cell lines with mean GI50 of 151.5 pM.

SG85 is a potent Enterovirus 3C protease inhibitor with EC50 of 180 nM against EV71 and 60 nM against human rhinovirus 14 in a live virus-cell-based assay.

SGC3027 is a histone methyltransferase inhibitor. SGC3027 is the first potent, selective and cell active chemical probe for PRMT7.

SGC-CBP30 is a potent CREBBP/EP300 inhibitor with IC50 of 21 nM and 38 nM, respectively.

SGC-iMLLT is the first small molecule chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with Kd of 129 and 77 nM respectively, IC50 of 0.26 uM (MLLT1).

SGD-1882 (PBD dimer, Pyrrolobenzodiazepine dimer) is a novel potent DNA-intercalating payload dimer (PBD dimer) payload for antibody-drug conjugates (ADCs)..

SGN-2FF is an orally bioavailable small molecule inhibitor of glycoprotein fucosylation, demonstrates encouraging preclinical antitumor activity in mouse models.

SGPL1-IN-28 is a novel S1P lyase inhibitor with in vitro IC50 of 120 nM, cell IC50 of 230 nM..

SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α.